| Aldeyra Therapeutics, Inc. (ALDX) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q1-CY2026 | Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | |
| Balance Sheet Date | 2025-Dec-31 | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | 2023-Sep-30 | 2023-Jun-30 | 2023-Mar-31 | 2022-Dec-31 | 2022-Sep-30 | 2022-Jun-30 | 2022-Mar-31 | 2021-Dec-31 | 2021-Sep-30 | 2021-Jun-30 | 2021-Mar-31 | 2020-Dec-31 | 2020-Sep-30 | 2020-Jun-30 | 2020-Mar-31 | 2019-Dec-31 | 2019-Sep-30 | 2019-Jun-30 | 2019-Mar-31 | 2018-Dec-31 | 2018-Sep-30 | 2018-Jun-30 | 2018-Mar-31 | 2017-Dec-31 | 2017-Sep-30 | 2017-Jun-30 | 2017-Mar-31 | 2016-Dec-31 | 2016-Sep-30 | 2016-Jun-30 | 2016-Mar-31 | 2015-Dec-31 | 2015-Sep-30 | 2015-Jun-30 | 2015-Mar-31 | 2014-Dec-31 | 2014-Sep-30 | 2014-Jun-30 | 2014-Mar-31 | |
| Fiscal Period | Q4-FY2025 | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | Q3-FY2023 | Q2-FY2023 | Q1-FY2023 | Q4-FY2022 | Q3-FY2022 | Q2-FY2022 | Q1-FY2022 | Q4-FY2021 | Q3-FY2021 | Q2-FY2021 | Q1-FY2021 | Q4-FY2020 | Q3-FY2020 | Q2-FY2020 | Q1-FY2020 | Q4-FY2019 | Q3-FY2019 | Q2-FY2019 | Q1-FY2019 | Q4-FY2018 | Q3-FY2018 | Q2-FY2018 | Q1-FY2018 | Q4-FY2017 | Q3-FY2017 | Q2-FY2017 | Q1-FY2017 | Q4-FY2016 | Q3-FY2016 | Q2-FY2016 | Q1-FY2016 | Q4-FY2015 | Q3-FY2015 | Q2-FY2015 | Q1-FY2015 | Q4-FY2014 | Q3-FY2014 | Q2-FY2014 | Q1-FY2014 | |
| Price to Sales | |||||||||||||||||||||||||||||||||||||||||||||||||
| Price to Book | 7.44x | 7.04x | 6.34x | 4.15x | 5.37x | 4.19x | 3.77x | 1.99x | 1.70x | 1.72x | 3.18x | 3.78x | 4.24x | 2.70x | 1.92x | 1.33x | 1.36x | 1.13x | 2.32x | 2.79x | 4.44x | 4.49x | 4.13x | 2.35x | 1.60x | 3.37x | 2.85x | 2.44x | 3.14x | 2.51x | 10.12x | 4.35x | 4.07x | 3.28x | 2.38x | ||||||||||||||
| Price to Earnings | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | ||||||||||||||
| Price to Unlevered FCF | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | |||||||||||||||||||||
| Debt to Asset Ratio | .39x | .37x | .35x | .32x | .32x | .27x | .22x | .20x | .19x | .16x | .17x | .18x | .17x | .14x | .13x | .14x | .12x | .11x | .09x | .14x | .29x | .22x | .26x | .31x | .36x | .34x | .09x | .11x | .09x | .23x | .15x | .12x | .10x | .07x | .12x | .11x | .14x | .12x | .10x | .12x | .12x | .08x | .07x | .13x | .28x | .20x | .17x | 1.39x | |
| Current Ratio | 2.58x | 2.72x | 2.86x | 6.49x | 5.59x | 6.80x | 4.55x | 6.50x | 6.64x | 6.81x | 9.96x | 10.50x | 11.78x | 7.83x | 12.36x | 13.60x | 19.77x | 20.66x | 34.59x | 13.26x | 6.69x | 13.65x | 14.52x | 12.84x | 5.82x | 6.36x | 11.40x | 9.17x | 11.18x | 4.81x | 8.11x | 11.07x | 13.11x | 20.28x | 12.47x | 13.06x | 10.93x | 11.05x | 13.82x | 12.89x | 13.28x | 22.73x | 24.32x | 15.34x | 6.60x | 12.23x | 10.05x | 3.12x | |